Industry News
Biotechnology Industry News
Takeda’s gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks
Takeda's gene therapy hunger not yet quelled as Evozyne pact extended for $400M in biobucks aarmstrong Tue, 04/05/2022 - 09:02
Phase 3 rare disease failure extends Theravance’s losing streak
Phase 3 rare disease failure extends Theravance's losing streak ntaylor Tue, 04/05/2022 - 08:38
Imara flunks phase 2b trials in sickle cell and thalassemia, wiping out clinical pipeline
Imara flunks phase 2b trials in sickle cell and thalassemia, wiping out clinical pipeline ntaylor Tue, 04/05/2022 - 07:48
Rough biotech market won’t stop 5AM Ventures’ new $750M life science funds
Rough biotech market won't stop 5AM Ventures' new $750M life science funds gmasson Mon, 04/04/2022 - 17:23
As FDA funding debated, CDER chief makes a pitch for more scientists—not a reorganization
As FDA funding debated, CDER chief makes a pitch for more scientists—not a reorganization mbayer Mon, 04/04/2022 - 17:18
CRISPR patent dispute not over yet as Emmanuelle Charpentier, universities appeal
CRISPR patent dispute not over yet as Emmanuelle Charpentier, universities appeal aarmstrong Mon, 04/04/2022 - 16:12
Through ‘serial de-risking,’ Sage is getting closer to building an Alzheimer’s contender
Through 'serial de-risking,' Sage is getting closer to building an Alzheimer's contender aarmstrong Mon, 04/04/2022 - 15:31
ACC: Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2b
ACC: Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2b mbayer Mon, 04/04/2022 - 10:21
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments aarmstrong Mon, 04/04/2022 - 09:47
Obesity may alter inflammation on a molecular level, throwing current treatments into question
Obesity may alter inflammation on a molecular level, throwing current treatments into question mbayer Mon, 04/04/2022 - 08:28
FDA puts Curis’ leukemia trial on partial hold after patient death spurs review of muscle breakdown
FDA puts Curis' leukemia trial on partial hold after patient death spurs review of muscle breakdown ntaylor Mon, 04/04/2022 - 07:54
Novartis says bye to Tsai as restructuring triggers the return of a familiar face
Novartis says bye to Tsai as restructuring triggers the return of a familiar face ntaylor Mon, 04/04/2022 - 04:54
Legend Biotech CSO abruptly leaves Johnson & Johnson’s CAR-T partner he co-founded
Legend Biotech CSO abruptly leaves Johnson & Johnson's CAR-T partner he co-founded aliu Fri, 04/01/2022 - 21:11
SAB vows to plow ahead with COVID-19 therapy after NIH drops out
SAB vows to plow ahead with COVID-19 therapy after NIH drops out aarmstrong Fri, 04/01/2022 - 10:06
Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024
Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024 mbayer Fri, 04/01/2022 - 10:02
Sage’s phase 2 Alzheimer’s drug shows signs of cognitive improvement—but there’s a catch
Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch aarmstrong Fri, 04/01/2022 - 09:33
With 2023 launch in sight, Pharming shares pivotal data on ex-Novartis rare disease drug
With 2023 launch in sight, Pharming shares pivotal data on ex-Novartis rare disease drug ntaylor Fri, 04/01/2022 - 08:03
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism ntaylor Fri, 04/01/2022 - 06:49
Layoff surge hits 3 more biotech companies
Layoff surge hits 3 more biotech companies gmasson Thu, 03/31/2022 - 18:08
Fierce Biotech Layoff Tracker: Novartis, bluebird add to pile of 30-plus biotechs laying off staff
Fierce Biotech Layoff Tracker: Novartis, bluebird add to pile of 30-plus biotechs laying off staff aarmstrong Thu, 03/31/2022 - 16:21